Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Share-based Compensation (2019 - 2025)

C4 Therapeutics' Share-based Compensation history spans 7 years, with the latest figure at $4.0 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 51.34% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $19.1 million, down 35.61%, while the annual FY2025 figure was $19.1 million, 35.61% down from the prior year.
  • Share-based Compensation reached $4.0 million in Q4 2025 per CCCC's latest filing, down from $4.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $8.9 million in Q1 2022 to a low of $3.8 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $6.4 million, with a median of $6.3 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: surged 3214.66% in 2021, then crashed 51.34% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $6.4 million in 2021, then rose by 8.91% to $6.9 million in 2022, then dropped by 8.09% to $6.4 million in 2023, then grew by 29.5% to $8.2 million in 2024, then plummeted by 51.34% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Share-based Compensation are $4.0 million (Q4 2025), $4.6 million (Q3 2025), and $5.0 million (Q2 2025).